The Investment Whisperer
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

The Investment Whisperer

Investing

FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

by admin September 20, 2024
September 20, 2024
FDA Fast Track Designation for Narmafotinib in Advanced Pancreatic Cancer

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to Amplia’s Focal Adhesion Kinase inhibitor, narmafotinib, for the treatment of advanced pancreatic cancer.

HIGHLIGHTS

The US FDA has granted Fast Track Designation to Amplia’s lead drug narmafotinib in advanced pancreatic cancerFast Track Designation facilitates the development of investigational drugs and allows for expedited review

Fast Track Designation is available to drugs that may provide an advantage over current therapies in the treatment of serious conditions. It is designed to speed the development of these drugs to enable patients to receive them sooner. This Designation will grant the Company access to more frequent meetings, and written communication, with the FDA. In future, narmafotinib may be eligible for Accelerated Approval and Priority Review. The Company has previously received Orphan Drug Designation from the FDA for narmafotinib in pancreatic cancer.

The Company’s CEO and Managing Director, Dr Chris Burns, commented, “Fast Track Designation for narmafotinib is a significant milestone for the Company. With this designation, we can work more closely with the FDA to accelerate our clinical program and gather the most compelling evidence for regulatory approval in this devastating disease.”

Amplia’s clinical trial in advanced pancreatic cancer, the ACCENT trial, is ongoing in Australia and South Korea. Earlier this year, the Company announced that the US FDA had cleared its IND1 application for a trial of narmafotinib in pancreatic cancer in the US. This trial is in advanced planning stages.

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

Click here for the full ASX Release

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
JPMorgan creates new role overseeing junior bankers as Wall Street wrestles with workload concerns
next post
What are Junior Miners and Are They a Good Investment? (Updated 2024)

Related Posts

Total Finland Gold Resources Increase to 961,800oz AuEq

May 29, 2025

NOVONIX Pens Synthetic Graphite Offtake Deal with Carmaker...

November 13, 2024

Top 5 NASDAQ Cybersecurity Stocks (Updated January 2025)

January 9, 2025

Major New LCT Pegmatite System Discovered at Mavis...

May 29, 2024

5 Small Biotech ETFs to Watch (Updated 2024)

March 12, 2024

$12M Proposed Cash Asset Sale to Strengthen Balance...

July 23, 2024

Investing in Graphene Companies

November 29, 2023

VRIC 2025: Experts Tout Hard Assets, Energy as...

January 23, 2025

Nuclear Fuels Announces Completion of Bought Deal Offering,...

January 25, 2024

Retraction re Mungana Processing Plant Capacity

April 15, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (1,458)
    • Investing (3,664)
    • Politics (4,922)
    • World (4,762)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheInvestmentWhisperer.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 TheInvestmentWhisperer.com | All Rights Reserved